What is headache? Common neurological disorders Headache disorders are among the most common neurological disorders. These include tension-type headache (TTH), migraine and chronic daily headache syndromes as well as the more rare disorders, cluster headache and trigeminal neuralgia. Underestimated and under-diagnosed Headache has been, and continues to be, underestimated in scope and scale and headache
Many of us may be guilty of describing a headache as a migraine, but there is a distinct difference. Migraine is not ‘just a headache’. It is a serious condition and can be frightening and utterly disabling. We all get stressed at work. And that’s not always a bad thing. Harnessed in the right way,
The first medicine designed to prevent migraines was approved by the Food and Drug Administration on Thursday, ushering in what many experts believe will be a new era in treatment for people who suffer the most severe form of these headaches. The drug, Aimovig, made by Amgen and Novartis, is a monthly injection with a
Move For Migraine Migraine remains an overlooked and misunderstood condition in many parts of Europe, including Belgium. The disease suffers from a lack of recognition and understanding, even from the first concerned parties (patients, caregivers, employers, etc.). This comes at a significant burden for the patients and at a high cost for society (1,650,000 working
INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least
For Industry. Cooperating in finding solutions for patients. WHAT CAN EMHA DO FOR THE INDUSTRY. Cooperating in finding solutions for patients. Working together is the only way to find effective and lasting solutions for migraine sufferers. By encouraging research, supporting projects and working to distribute reliable information, we can achieve a better quality of life
First monoclonal antibody therapy for prevention of Migraine Aimovig recommended for marketing authorization 01/06/2018 The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Aimovig (erenumab), the first human monoclonal antibody therapy for prevention of migraine. Aimovig belongs to a new class of medicines that work by blocking the activity
Listen to the song created by The German Cluster Headache association.
We are an alliance The European Migraine and Headache Alliance is a non-profit patient association, which functions as an umbrella organisation for different patient groups across Europe. The Alliance was establi- shed in 2006 and since then we represent more than 30 patient groups across the continent. Also, we work closely with International Associates in Canada, US, Turkey, Argentina,
After launching The Migraine Movement Manifesto, from EMHA, we set the goal to inform the largest amount of European migraine sufferers about the existence of that movement, born with the aim of giving them visibility, answers and support.
